INM004

DRUG3 trials

Sponsors

Inmunova S.A.

Conditions

Bloody DiarrheaDiarrhea-Associated Hemolytic Uremic SyndromeHemolytic-Uremic SyndromePediatric Kidney DiseaseSTEC, Unspecified

Phase 2

Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS

TerminatedNCT04132375

Inmunova S.A.Bloody Diarrhea, Hemolytic-Uremic Syndrome, Pediatric Kidney Disease +1

Start: 2019-07-17End: 2022-07-19Updated: 2023-07-19

A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS

CompletedNCT05569746

Inmunova S.A.Diarrhea-Associated Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Pediatric Kidney Disease

Start: 2022-10-06End: 2023-07-14Updated: 2023-08-21

Phase 3

Efficacy of INM004 in Children With STEC-HUS

RecruitingNCT06389474

Inmunova S.A.Hemolytic-Uremic Syndrome

Start: 2024-10-05End: 2026-12-31Target: 220Updated: 2026-01-15

Related Papers

Serology as an early diagnostic tool in pediatric patients with Shiga toxin-producing <i>Escherichia coli</i>-associated hemolytic uremic syndrome: a <i>post hoc</i> analysis of a phase 2 clinical trial.

2026-02-27